Posts

Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol

Author: Brenda K.Colasanti, Charles R. Craig, R. David Allara Published in Science Direct September 1984 Abstract Cannabinol or cannabigerol was administered to cats topically in doses of 250, 500 and 1000 μg as a single drop or chronically via osmotic minipumps (20 μg hr−1) over a period of 9 days. While cannabinol had a modest…

A national survey of US emergency medicine physicians on their knowledge regarding state and federal cannabis laws.

Author: Kevin M. Takakuwa, Frances S. Shofer, and Raquel M. Schears. Published in Mary Ann Liebert, Inc, Publishers February 2020 Abstract Introduction Medical cannabis laws have been passed in 33 U S States but cannabis remains federally illegal Eleven states additionally allow for adult use recreational Studies report and increase in Emergency Department ED use when…

The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage

Author: Kevin M. Takakuwa, Jeffrey Y. Hergenrather, Frances S. Shofer, and Raquel M. Schears Published in Mary Ann Liebert, Inc. Publishers January 2020 Abstract Objectives: To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design: Retrospective cohort study. Setting: A single-center cannabis medical practice site…

Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort

Author: Eric P. Baron, Philippe Lucas, Joshua Eades & Olivia Hogue Published in The Journal of Headache and Pain May 2018 Abstract Background  Medicinal cannabis registries typically report pain as the most common reason for use. It would be clinically useful to identify patterns of cannabis treatment in migraine and headache, as compared to arthritis and…

Totality of the Evidence Suggests Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and Critical Review

Author: Ciara A. Torres, Christopher Medina-Kirchner, Kate Y. O’Malley, and Carl L. Hart Published in Frontiers in Psychology May 2020 Abstract Background Despite limited data demonstrating pronounced negative effects of prenatal cannabis exposure, popular opinion and public policies still reflect the belief that cannabis is fetotoxic. Methods This article provides a critical review of results from…

Cannabis and Psychosis: a Critical Overview of the Relationship

Authors: Charles Ksir, Carl L Hart Published in Current Psychiatry Reports February 2016 Abstract Interest in the relationship between cannabis use and psychosis has increased dramatically in recent years, in part because of concerns related to the growing availability of cannabis and potential risks to health and human functioning. There now exists a plethora of scientific…

Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

Author: Eric P. Baron DO Published in HEADACHE Journal of Headache and face pain August 2018 Abstract Background Comprehensive literature reviews of historical perspectives and evidence supporting cannabis/cannabinoids in the treatment of pain, including migraine and headache, with associated neurobiological mechanisms of pain modulation have been well described. Most of the existing literature reports on the…

Antibacterial Cannabinoids from Cannabis Sativa: A Structure-Activity Study

Authors: Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith,and M. Mukhlesur Rahman Published in Journal of Natural Products August 2008 Abstract Marijuana (Cannabis sativa) has long been known to contain antibacterial cannabinoids, whose potential to address antibiotic resistance has not yet been investigated. All five major cannabinoids (cannabidiol (1b), cannabichromene…

Medical Cannabis for the Treatment of Fibromyalgia

Authors: George Habib, Suheil Artul Published in Journal of Clinical Rheumatology August 2018 Abstract Background Fibromyalgia is a chronic pain syndrome, characterized by chronic musculoskeletal pain, fatigue, and mood disturbances. There are nearly no data on the effect of medical cannabis (MC) treatment on patients with fibromyalgia. Methods Data were obtained from the registries of 2…

A Scoping Review of the Use of Cannabis and Its Extracts as Potential Harm Reduction Strategies: Insights from Preclinical and Clinical Research

Authors: James Siklos-Whillans, Alia Bacchus, Laurie A. Manwell Published in International Journal of Mental Health and Addiction March 2020 Abstract Cannabis as a harm reduction strategy (HRS) is supported by evidence demonstrating its efficacy for pain relief and as a substitution for alcohol, illicit drugs, and pharmaceuticals. Animal models show cannabinoids reduce the effects of opiate…

Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms

Authors: Marieka V. DeVuono, Linda A. Parker Published in Mary Ann Liebert, Inc Publishers June 2020 Abstract Introduction Cannabinoids have long been known for their ability to treat nausea and vomiting. Recent reports, however, have highlighted the paradoxical proemetic effects of cannabinoids. Cannabinoid hyperemesis syndrome (CHS) is characterized by cyclical episodes of nausea and vomiting, accompanied…

Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study

Authors: Joshua Aviram, Yelena Vysotski, Paula Berman, Gil M Lewitus, Elon Eisenberg, David Meiri Published in MDPI June 2020 Background Medical cannabis (MC) treatment for migraine is practically emerging, although sufficient clinical data are not available for this indication. This cross-sectional questionnaire-based study aimed to investigate the associations between phytocannabinoid treatment and migraine frequency. Methods:…